Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Controlled Trial of Sintilimab in Combination with Chemotherapy ± Local Treatment for Oligometastatic Esophagogastric Junction/Gastric Adenocarcinoma

NCT06739161 is registered in ClinicalTrials.gov with Jiangsu Cancer Institute & Hospital as lead sponsor.

NCT NCT06739161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06739161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Controlled Trial of Sintilimab in Combination with Chemotherapy ± Local Treatment for Oligometastatic Esophagogastric Junction/Gastric Adenocarcinoma
Lead sponsor
Jiangsu Cancer Institute & Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 2, 2024
Completion date
December 2, 2028
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal junction adenocarcinoma